Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Sesquient Patent Expiration

Sesquient is a drug owned by Lupin Inc. It is protected by 5 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2033. Details of Sesquient's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(7 years from now)

Active
US9750822 Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(3 years from now)

Active
US9200088 Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(3 years from now)

Active
US8410077 Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(3 years from now)

Active
US7635773 Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(3 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Sesquient is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sesquient's family patents as well as insights into ongoing legal events on those patents.

Sesquient's Family Patents

Sesquient has patent protection in a total of 14 countries. It's US patent count contributes only to 26.9% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Sesquient.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Sesquient's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Sesquient Generic API suppliers:

Fosphenytoin Sodium is the generic name for the brand Sesquient. 12 different companies have already filed for the generic of Sesquient, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sesquient's generic





About Sesquient

Sesquient is a drug owned by Lupin Inc. Sesquient uses Fosphenytoin Sodium as an active ingredient. Sesquient was launched by Lupin in 2020.

Approval Date:

Sesquient was approved by FDA for market use on 05 November, 2020.

Active Ingredient:

Sesquient uses Fosphenytoin Sodium as the active ingredient. Check out other Drugs and Companies using Fosphenytoin Sodium ingredient

Dosage:

Sesquient is available in solution form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION Discontinued INTRAVENOUS
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION Discontinued INTRAVENOUS